Halozyme Therapeutics, Inc. Aktie News

Halozyme's $750M Elektrofi acquisition expands its drug delivery leadership beyond ENHANZE into high-concentration biologic formulations. Elektrofi's Hypercon enables 400–500 mg/mL formulations for ≤2 mL self-injections, complementing ENHANZE rather than cannibalizing it. Existing partners like Lilly, Argenx, and J&J are already aligned, with first-in-human Hypercon studies expected within 12–1...

SAN DIEGO , Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m.

Halozyme Therapeutics (HALO) stock could be a solid choice to leverage the current momentum. Why? Because it offers strong margins, a low-debt capital structure, reasonable valuation, and strong momentum.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Director Conference Call Participants Morgan Gryga - Morgan Stanley, Research Division Brendan Smith - TD Cowen, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Divi...

Halozyme Therapeutics said on Wednesday it will buy privately held Elektrofi for $750 million in cash, to expand its lineup with a technology that can deliver biologic medicines in small, concentrated doses.

Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants Helen Torley - President, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone. Welcome to Morgan Stanley's Global ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT Company Participants Helen Torley - President, CEO & Director Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Awesome. Thank you very much for joining us today.